Assuntos
Asma/diagnóstico , Testes de Provocação Brônquica/economia , Broncoconstritores/farmacologia , Análise Custo-Benefício , Cloreto de Metacolina/farmacologia , Adolescente , Adulto , Asma/economia , Asma/imunologia , Testes de Provocação Brônquica/instrumentação , Testes de Provocação Brônquica/métodos , Broncoconstritores/imunologia , Feminino , Humanos , Masculino , Cloreto de Metacolina/imunologia , Pessoa de Meia-IdadeRESUMO
No disponible
Assuntos
Humanos , Masculino , Feminino , Cloreto de Metacolina/efeitos adversos , Cloreto de Metacolina/análise , Cloreto de Metacolina/economia , Asma/tratamento farmacológico , Asma/economia , Análise Custo-Benefício/normas , Análise Custo-Benefício , 50303 , Índice de Massa CorporalRESUMO
The current guidelines recommend an approach to asthma management based on asthma control, rather than asthma severity. Although several specific questionnaires have been developed and control criteria have been established based on clinical guidelines, the evaluation of asthma control is still not optimal. In general, these indicators provide adequate assessment of current control, but they are more limited when estimating future risk. There is much evidence demonstrating the persistence of airway inflammation and airway hyperresponsiveness (AHR) in patients with total control. Therefore, the objective of this review was to analyse the possible role of AHR monitoring as an instrument for assessing asthma control. We will evaluate its capacity as an indicator for future risk, both for estimating the possibility of clinical deterioration and loss of lung function or exacerbations. Furthermore, its relationship with inhaled corticosteroid treatment will be analysed, while emphasizing its capacity for predicting response and adjusting dosage, as well as information about the capability of AHR for monitoring treatment. Last of all, we will discuss the main limitations and emerging opportunities of AHR as an assessment instrument for asthma control.
